Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.

Antimicrobial agents and chemotherapy - 1 Aug 2014

Bilello J P, Lallos L B, McCarville J F, La Colla M, Serra I, Chapron C, Gillum J M, Pierra C, Standring D N, Seifer M

Abstract excerpt

The hepatitis C virus (HCV) nonstructural 5A (NS5A) protein is a clinically validated target for drugs designed to treat chronic HCV infection. This study evaluated the in vitro activity, selectivity, and resistance profile of a novel anti-HCV compound, samatasvir (IDX719), alone and in combination with other antiviral agents. Samatasvir was effective and selective against infectious HCV and replicons, with 50%...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Gene Expression Regulation, Viral

Share to Hep G2 Cells

Share to Replicon

Share to Ribavirin

Share to Viral Nonstructural Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 24867983
DOI: 10.1128/AAC.02777-13
PMCID: PMC4136001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.PMID 24867983Read ↗

A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.Semantic proximity Read ↗

In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A.Semantic proximity Read ↗

In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir.Semantic proximity Read ↗

Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.Semantic proximity Read ↗

Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A.Semantic proximity Read ↗

In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.Semantic proximity Read ↗

Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.Semantic proximity Read ↗

Identification of hepatitis C virus NS5A inhibitors.Semantic proximity Read ↗

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations.Semantic proximity Read ↗

Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.Semantic proximity Read ↗

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.Semantic proximity Read ↗

Hepatitis C Virus Drugs Simeprevir And Grazoprevir Synergize with Remdesivir to Suppress SARS-CoV2 ReplicationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.